Beckwith-Wiedemann syndrome (BWS) is fetal overgrowth syndrome, whereas Silver-Russell syndrome (SRS) is characterized by pre-or postnatal growth retardation. BWS and SRS share molecular epigenetic defects in chromosome 11p15, where two imprinting centers, LIT1-differentially methylated region (MDR) and H19-DMR, exist. A small number of patients with SRS harbor maternal uniparental disomy of chromosome 7q as well. Extensive genetic analyses including methylation specific (MS) PCR-RFLP, MS-MLPA, microsatellite markers or MS-pyrosequencing analysis were performed using genomic DNA obtained from peripheral leukocytes to identify the epigenetic detects in patients with BWS and SRS. Ten out of 14 BWS patients (71.4%) showed hypomethylation in LIT1-DMR. One BWS patient harbored hypermethylation in H19-DMR (7.1%). Two BWS patients had both H19-DMR and LIT1-DMR defects, one of whom has paternal UPD at chr. 11 (14.3%). Eleven out of 13 SRS patients (78.6 %) showed hypomethylation in H19-DMR. One SRS patient (6.7%) had UPD at 7q. With MS-pyrosequencing analysis, epigenetic defects were identified in 93.1% of BWS patients and 85.7% of SRS patients. These positive rates are higher than previously reported positive rates, 80% in BWS and 50% in SRS. In addition, with MS-pyrosequencing analyses, quantification of methylation defects was available, which could identify partial methylation defects that were not revealed by MS-PCR-RFLP or MS-MLPA. The validity of MS-pyrosequencing method for the genetic diagnosis of BWS or SRS is needed to be investigated in a large patient cohort.
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